Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16028488 | 0.79 | CYP2C19 (0.49) | LMNACYP2C19 | |
| SCHEMBL20077526 | 0.79 | — | — | |
| SCHEMBL21432044 | 0.78 | POLB (0.33) | POLB | |
| SCHEMBL12329471 | 0.78 | CYP2C19 (0.51) | LMNACYP2C19 | |
| SCHEMBL16076177 | 0.75 | CYP2C19 (0.44) | LMNACYP2C19 | |
| SCHEMBL27370503 | 0.73 | DRD2 (0.33) | LMNACYP2C19 | |
| SCHEMBL7296150 | 0.73 | CYP2C19 (0.37) | LMNACYP2C19 | |
| SCHEMBL20128071 | 0.73 | CYP2C19 (0.38) | LMNACYP2C19POLB | |
| SCHEMBL23253661 | 0.73 | POLB (0.34) | LMNAPOLB | |
| SCHEMBL23037193 | 0.71 | CYP2C19 (0.34) | LMNACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110049985-B | Heterocyclic sulfones as ROR gamma modulators | 百时美施贵宝公司 | 2022-05-31 | — | — | CN | disclosed |
| EP-3526218-B1 | HETEROCYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10934286-B2 | Heterocyclic sulfones as ROR gamma modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3541786-B1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10435369-B2 | Tricyclic sulfones as ROR gamma modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190300523-A1 | HETEROCYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-10-03 | — | — | US | disclosed |
| WO-2018089402-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20180127368-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-05-10 | — | — | US | disclosed |
| US-20180127368-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-05-10 | — | — | US | disclosed |
| WO-2018071620-A1 | HETEROCYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435369-B2 | Tricyclic sulfones as ROR gamma modulators | RORC, RORB, RORA | LMNA 3927/4885CYP2C19 318/4885POLB 3591/4885 |
| US-20190300523-A1 | HETEROCYCLIC SULFONES AS ROR GAMMA MODULATORS | RORC, RORB, RORA | LMNA 3885/4885CYP2C19 332/4885POLB 3811/4885 |
| US-10934286-B2 | Heterocyclic sulfones as ROR gamma modulators | RORC, RORB, RORA | LMNA 3885/4885CYP2C19 332/4885POLB 3811/4885 |
| US-20180127368-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | RORC, RORB, RORA | LMNA 3927/4885CYP2C19 318/4885POLB 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.